Holen Sie sich die Stockscreener-App
1.63
3.55%
-0.06
Handel nachbörslich:
1.63
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - Sahm
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN
Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada
Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com South Africa
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com
Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart
Coherus BioSciences Q4 2025 earnings preview - MSN
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Q4 2025 Earnings Call Transcript - MarketBeat
Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: St - GuruFocus
Coherus Oncology (CHRS) Sees Strong Growth with LOQTORZI - GuruFocus
Coherus Oncology Reports Q4 Earnings Loss - National Today
Coherus Oncology Q4 Earnings Call Highlights - MarketBeat
CHRS Q4 Revenue Falls Short but Strategic Shift Shows Promise - GuruFocus
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual ProfitNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Coherus Oncology: Fourth Quarter Financial Results Overview - Bitget
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Coherus Oncology: Q4 Earnings Snapshot - Barchart.com
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect - GuruFocus
Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts - National Today
Coherus Oncology Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Coherus BioSciences's Earnings Outlook - Benzinga
How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks - Yahoo Finance
Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com
CHRS: Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth - TradingView
CHRS: Rapid oncology transformation, strong LOQTORZI growth, and promising pipeline assets drive outlook - TradingView
Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow - Quiver Quantitative
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewswire
Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday - MarketBeat
CHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 90+ Key Companies | DelveInsight - StreetInsider
Hepatocellular Carcinoma Clinical Trial Pipeline Shows - openPR.com
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 (NASDAQ:CHRS) - Seeking Alpha
Coherus Oncology announces proposed public offering of common stock - MSN
How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS) - Yahoo Finance
Coherus closes $50.1 million public offering of common stock - Investing.com Australia
Coherus Biosciences Completes $47 Million Equity Offering - TipRanks
Coherus closes $50.1 million public offering of common stock By Investing.com - Investing.com UK
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - The Manila Times
Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs - Stock Titan
Coherus Oncology (NASDAQ: CHRS) raises $47M through common stock offering - Stock Titan
More drugmakers are turning to cancer combos. Will it help patients live longer? - PharmaVoice
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Analysts - MarketBeat
Coherus Oncology prices $50.1 million public offering of common stock By Investing.com - Investing.com Canada
Coherus BioSciences stock falls after pricing $50.1 million share offering By Investing.com - Investing.com Australia
CHRS Should I Buy - Intellectia AI
CHRS Successfully Completes Joint Book-Running Offering - GuruFocus
Coherus Oncology prices stock offering to raise $50.1M - MSN
Latham & Watkins Advises Coherus Oncology on Public Offering of Common Stock - Latham & Watkins LLP
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):